TriSalus Life Sciences, Inc.
TLSI
$4.20
$0.122.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.41% | 49.52% | 45.50% | 46.21% | 59.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.41% | 49.52% | 45.50% | 46.21% | 59.00% |
| Cost of Revenue | 69.75% | 85.04% | 80.65% | 58.79% | 57.50% |
| Gross Profit | 50.77% | 44.26% | 40.55% | 44.29% | 59.25% |
| SG&A Expenses | 14.52% | 13.49% | 11.23% | 8.50% | 20.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.91% | 2.45% | -8.44% | -13.16% | -4.42% |
| Operating Income | 25.49% | 27.08% | 36.00% | 38.41% | 27.84% |
| Income Before Tax | -30.56% | 28.78% | 42.90% | 57.64% | 49.34% |
| Income Tax Expenses | 16.67% | -25.00% | -118.18% | -52.94% | -33.33% |
| Earnings from Continuing Operations | -30.56% | 28.78% | 42.91% | 57.64% | 49.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.56% | 28.78% | 42.91% | 57.64% | 49.34% |
| EBIT | 25.49% | 27.08% | 36.00% | 38.41% | 27.84% |
| EBITDA | 25.69% | 27.43% | 36.53% | 39.05% | 28.35% |
| EPS Basic | -34.07% | 21.26% | 55.11% | 97.07% | 96.51% |
| Normalized Basic EPS | 39.03% | 48.83% | 68.45% | 95.48% | 95.33% |
| EPS Diluted | -34.07% | 21.26% | 55.11% | 97.07% | 96.51% |
| Normalized Diluted EPS | 39.03% | 48.83% | 68.45% | 95.48% | 95.33% |
| Average Basic Shares Outstanding | 49.51% | 36.27% | 38.19% | 76.96% | 91.03% |
| Average Diluted Shares Outstanding | 49.51% | 36.27% | 38.19% | 76.96% | 91.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |